

NEWSLETTER

CHEMICAL & PHARMACEUTICAL 26 January - 1 February 2026



India revokes mandatory BIS certification for polyester products resuming trade with China

The Indian Chemicals and Petrochemicals Department issued a notice officially revoking the mandatory BIS certification for 14 core products in the polyester industry chain, including purified terephthalic acid, ethylene glycol, and polyester filament. This policy reversal clears an obstacle to Sino-Indian polyester trade, allowing these products to move beyond the mandatory certification access model and return to free circulation. **(ChemNet Chemical Industry Headlines)**

The development of China's high-end nylon industry

Tianchen Qixiang New Materials Co., Ltd., achieved full production of its 200,000-ton/year adiponitrile plant. This project is China's first industrial-scale production project using the butadiene method for adiponitrile, breaking the long-term foreign technological monopoly and saving downstream companies approximately 10 billion yuan (€1.22 billion) in procurement costs annually. **(ChemNet Chemical Industry Headlines)**

CNCEC disclosed significant technological application progress on its interactive platform

China National Chemical Engineering Group Co., Ltd. (CNCEC) stated that its Nylon 66 and aerogel products are already applicable to commercial aerospace materials, filling some gaps in domestic applications of related materials. CNCEC has established a core R&D system focused on high-performance fibers, new high-end nylon materials, and biodegradable plastics. **(ChemNet Chemical Industry Headlines)**

China rolls out domestic HPV (human papillomavirus) vaccine for cervical cancer prevention

China has launched its domestic nine-valent HPV vaccine for females aged 9 to 45. The rollout began in Xiamen, offering protection against cervical cancer. Dosage varies, with two shots for younger recipients and three for adults. The vaccine is a key preventative measure, with high efficacy against HPV infection. This marks a significant step in China's public health efforts against cervical cancer. **(Xinhua)**

Domestic pharma firm CR Sanjiu delivers growth in scale, profitability

CR (China Resources) Sanjiu reported strong growth during the 14th Five-Year Plan (2021-2025), with revenue and profit growing at 23.6% and 24.5% annually. The company invested heavily in R&D, increasing spending by 64% since 2020, while distributing dividends five times its fundraising amount. Its sustainability efforts earned an 'A' MSCI ESG rating in 2025. **(China Daily)**